Xuefuzhuyu Decoction on contrast induced nephropathy after percutaneous coronary intervention

doi:10.3969/j.issn.1004-583X.2018.02.014

Abstract

Abstract: Objective To investigate the protective effect of Xuefuzhuyu Decoction in patients with contrast agent nephropathy after percutaneous coronary intervention (PCI).Methods A total of 240 patients was enrolled and randomly divided into two groups: Control group (n=120) and Observation group (n=120). Before and after PCI， all the patients were routinely given antiplatelets， lipid regulation， hydration therapy， and were not fasting. Based on the routine therapy， observation group was given Xuefuzhuyu Decoction once a day before 3 days PCI and after 3 days of PCI. Serum creatinine (SCr)， estimated glomerular filtration rate (eGFR)， superoxide dismutase (SOD) and malondialdehyde (MDA) were measured respectively before and after PCI.Results Compared with Control group， observation group presented a lower fluctuation of SCr and eGFR(P<0.01) Moreover， MDA content was significantly lower than that in the conventional group (P<0.05) and SOD was significantly higher than that in the conventional group (P<0.05).Conclusion The medication of Xuefuzhuyu Decoction before and after PCI may effectively reduce the incidence of contrast agent nephropathy. The mechanism may be related to the removal of oxygen radicals and the decrease of contrast agent viscosity.

Key words: Xuefuzhuyu decoction, angioplasty, contrast agent nephropathy

Liu Huahua， Tang Weiliang， Yang Fangfang， Zhao Jingjing， Peng Fang. Xuefuzhuyu Decoction on contrast induced nephropathy after percutaneous coronary intervention[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2018.02.014.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2018.02.014

https://huicui.hebmu.edu.cn/EN/Y2018/V33/I2/145

[1]	Wang Wenqi, Ma Hongfang, Du Yaping, Ding Haixia, Bai Lei, Wang Fujun. Therapeutic effect of chocolate balloon dilatation angioplasty on diabetic infrapopliteal artery occlusion [J]. Clinical Focus, 2021, 36(4): 336-339.
[2]	Sun Wei. Prediction of no reflow phenomenon in patients with acute myocardial infarction undergoing coronary intervention by CHA2DS2VASc score [J]. Clinical Focus, 2020, 35(9): 792-795.
[3]	Su Yongcai, Zhang Xiaole, Huang Zhifeng, Feng Xinwu, Su Liangxian. Clinical analysis of interventional therapy in patients with acute ST segment elevation myocardial infarction in hyperacute stage [J]. Clinical Focus, 2020, 35(6): 513-516.
[4]	Li Sixue, Gu Guoqiang, Liu Demin, Wang Qian, Zhang Guangming, Cui Wei. Monocyte to highdensity lipoprotein cholesterol ratio can not predict contrast induced nephropathy in patients after PCI [J]. Clinical Focus, 2020, 35(4): 307-311.
[5]	Wang Haiyan1, Tian Li1, Zhao Ying2, Li Zhijuan1, Shi Jianping1, Fu Xianghua3. Effects of early heparin therapy on patients with acute STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention [J]. Clinical Focus, 2020, 35(2): 134-138.
[6]	He Zhengfei, Wang Diqing, He Xiaolan, Sun Linggang. Related factors of slow coronary flowno reflow after percutaneous coronary angioplasty for acute coronary syndrome [J]. Clinical Focus, 2020, 35(11): 971-975.
[7]	Yuan Simin, Zhao Xiufeng, Xin Shuanli, Chang Chao, Liu Lijun, Han Liying. Case series experience of GuidezillaTM extension catheter [J]. Clinical Focus, 2019, 34(8): 720-723.
[8]	He Jinsen1, Lu Linqi1, Yao Ying2. Metaanalysis of percutaneous cutting balloon angioplasty for the treatment of hemodialysis stenosis [J]. Clinical Focus, 2019, 34(11): 1004-1009.
[9]	Wang Li1, Yu Tao2. Analysis of influencing factors of in stent restenosis after percutaneous coronary intervention in patients with coronary heart disease [J]. Clinical Focus, 2018, 33(8): 675-677,682.
[10]	Wei Zhenheng, Zhang Juntang. PCI preoperative single load dose and conventional dose risuvastatin on prognosis of patients with coronary heart disease [J]. Clinical Focus, 2018, 33(6): 494-497.
[11]	Huang Ping， Wang Xiaodong， Wang Wei. Impact of multivessel coronary disease on inhospital outcome in acute coronary syndrome patients undergoing primary percutaneous coronary intervention [J]. Clinical Focus, 2018, 33(2): 122-124,128.
[12]	Xiang Jun, Liu Cheng, Wang Yan, Wang Lei, Li Wei, He Haiyan, Cao Na, Pan Lei. Influence of preinform template on time of informed consent for primary percutaneous coronary intervention in patients with acute myocardial infarction [J]. Clinical Focus, 2018, 33(12): 1049-1052.
[13]	Wei Liye， Xia Yue， Qi Guoqing， Zhao Hongliang. Effect of nicorandil on cardiac function and exercise tolerance in patients with non-ST-elevation myocardial infarction after elective percutaneous coronary intervention [J]. Clinical Focus, 2017, 32(9): 755-758.
[14]	Pan Guangjie，Chen Huili，Gu Yunfei，Liu Lei，Chen Yan，Li Songsen，Ma Huifang，Jin Jun，Zhang Shouyan. Current situation and related factors of coronary intervention treatment in patients with non STelevation acute coronary syndrome [J]. Clinical Focus, 2017, 32(7): 591-594.
[15]	Liu Xiaoyu，Jia Guowei，Sun Rongguo，Ma Bocong，Zhao Ming，Zhang Hongbin，Zhang Wei. Ticagrelor and clopidogrel on PCI perioperative hsCRP in patients with acute coronary syndrome [J]. Clinical Focus, 2017, 32(5): 421-424.

Xuefuzhuyu Decoction on contrast induced nephropathy after percutaneous coronary intervention

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments